This is a Validated Antibody Database (VAD) review about human KLRC4-KLRK1, based on 40 published articles (read how Labome selects the articles), using KLRC4-KLRK1 antibody in all methods. It is aimed to help Labome visitors find the most suited KLRC4-KLRK1 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
BioLegend
mouse monoclonal (1D11)
  • flow cytometry; human; loading ...; fig 4a
BioLegend KLRC4-KLRK1 antibody (BioLegend, 1D11) was used in flow cytometry on human samples (fig 4a). J Immunol (2019) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human; loading ...; fig 2a
BioLegend KLRC4-KLRK1 antibody (Biolegend, 1D11) was used in flow cytometry on human samples (fig 2a). Front Immunol (2019) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human; loading ...; fig s1d
BioLegend KLRC4-KLRK1 antibody (Biolegend, 1D11) was used in flow cytometry on human samples (fig s1d). Proc Natl Acad Sci U S A (2018) ncbi
mouse monoclonal (1D11)
  • mass cytometry; human; loading ...; fig 4f
BioLegend KLRC4-KLRK1 antibody (Biolegend, 1D11) was used in mass cytometry on human samples (fig 4f). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human; loading ...; fig 5c
BioLegend KLRC4-KLRK1 antibody (Biolegend, 1D11) was used in flow cytometry on human samples (fig 5c). J Immunol (2017) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human; loading ...; fig s6a
BioLegend KLRC4-KLRK1 antibody (Biolegend, 1D11) was used in flow cytometry on human samples (fig s6a). Front Immunol (2017) ncbi
mouse monoclonal (1D11)
  • ELISA; human; 5 ug/ml; loading ...; fig 1a
In order to identify cellular changes induced by IL-2, BioLegend KLRC4-KLRK1 antibody (BioLegend, 1D11) was used in ELISA on human samples at 5 ug/ml (fig 1a). J Immunol (2017) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human; loading ...; fig 4e
BioLegend KLRC4-KLRK1 antibody (BioLegend, 1D11) was used in flow cytometry on human samples (fig 4e). Oncotarget (2017) ncbi
mouse monoclonal (1D11)
  • flow cytometry; mouse; fig 5b
BioLegend KLRC4-KLRK1 antibody (BioLegend, 1D11) was used in flow cytometry on mouse samples (fig 5b). Nat Commun (2016) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human; fig 1a
In order to assess the effects of platelet-derived ectosomes on natural killer cells, BioLegend KLRC4-KLRK1 antibody (BioLegend, 1D11) was used in flow cytometry on human samples (fig 1a). J Immunol (2016) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human; loading ...; fig 5a
BioLegend KLRC4-KLRK1 antibody (Biolegend, 1D11) was used in flow cytometry on human samples (fig 5a). J Biol Chem (2016) ncbi
mouse monoclonal (1D11)
  • blocking or activating experiments; human; fig 8
BioLegend KLRC4-KLRK1 antibody (Biolegend, 1D11) was used in blocking or activating experiments on human samples (fig 8). PLoS Pathog (2015) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human
BioLegend KLRC4-KLRK1 antibody (Biolegend, 320808) was used in flow cytometry on human samples . Scand J Immunol (2015) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human
BioLegend KLRC4-KLRK1 antibody (BioLegend, 1D11) was used in flow cytometry on human samples . J Immunol (2015) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human; fig 3
BioLegend KLRC4-KLRK1 antibody (BioLegend, 1D11) was used in flow cytometry on human samples (fig 3). Oncol Rep (2015) ncbi
mouse monoclonal (1D11)
  • flow cytometry; African green monkey
BioLegend KLRC4-KLRK1 antibody (Biolegend, 1D11) was used in flow cytometry on African green monkey samples . Int Immunol (2014) ncbi
Invitrogen
mouse monoclonal (5C6)
  • flow cytometry; human; loading ...; fig s2
Invitrogen KLRC4-KLRK1 antibody (eBioscience, 12-5879-42) was used in flow cytometry on human samples (fig s2). BMC Cancer (2019) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human; loading ...; fig s10b
Invitrogen KLRC4-KLRK1 antibody (eBiosciences, 1D11) was used in flow cytometry on human samples (fig s10b). PLoS Pathog (2016) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human; fig 2
In order to study chronic hepatitis C virus infections and the functional dichotomy of V-delta2 gamma-delta T cells and their role in cytotoxicity and not IFN-gamma production, Invitrogen KLRC4-KLRK1 antibody (eBioscience, 1D11) was used in flow cytometry on human samples (fig 2). Sci Rep (2016) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human
Invitrogen KLRC4-KLRK1 antibody (eBioscience, 1D11) was used in flow cytometry on human samples . Eur J Immunol (2015) ncbi
mouse monoclonal (1D11)
  • immunocytochemistry; human
Invitrogen KLRC4-KLRK1 antibody (eBioscience, 1D11) was used in immunocytochemistry on human samples . J Immunol (2014) ncbi
R&D Systems
mouse monoclonal (149810)
  • blocking or activating experiments; human; loading ...; fig 5a
R&D Systems KLRC4-KLRK1 antibody (R&D Systems, 149810) was used in blocking or activating experiments on human samples (fig 5a). J Virol (2018) ncbi
mouse monoclonal (149810)
  • flow cytometry; human; loading ...
In order to identify cellular changes induced by IL-2, R&D Systems KLRC4-KLRK1 antibody (R&D Systems, 149810) was used in flow cytometry on human samples . J Immunol (2017) ncbi
mouse monoclonal (149810)
  • blocking or activating experiments; human; loading ...; fig 5
R&D Systems KLRC4-KLRK1 antibody (R&D Systems, 149810) was used in blocking or activating experiments on human samples (fig 5). J Exp Med (2017) ncbi
mouse monoclonal (149810)
  • blocking or activating experiments; human; loading ...; fig s14b
  • flow cytometry; human
In order to investigate NF-KB signaling in natural killer cells, R&D Systems KLRC4-KLRK1 antibody (R&D Systems, 149810) was used in blocking or activating experiments on human samples (fig s14b) and in flow cytometry on human samples . Nat Commun (2016) ncbi
Santa Cruz Biotechnology
mouse monoclonal (5C6)
  • blocking or activating experiments; human; fig 5
Santa Cruz Biotechnology KLRC4-KLRK1 antibody (Santa Cruz, sc-53501) was used in blocking or activating experiments on human samples (fig 5). Oncoimmunology (2016) ncbi
mouse monoclonal (5C6)
  • other; human; loading ...; fig st1
In order to use size exclusion chromatography-microsphere-based affinity proteomics to study clinical samples obtained from pediatric acute leukemia patients, Santa Cruz Biotechnology KLRC4-KLRK1 antibody (SCBT, 5C6) was used in other on human samples (fig st1). Mol Cell Proteomics (2016) ncbi
Bio-Rad
mouse monoclonal (1D11)
  • immunohistochemistry; dogs; 1:25
In order to compare two treatment regiments for idiopathic inflammatory bowel disease, Bio-Rad KLRC4-KLRK1 antibody (Serotec, 1D11) was used in immunohistochemistry on dogs samples at 1:25. PLoS ONE (2014) ncbi
Abcam
mouse monoclonal (1D11)
  • flow cytometry; human
Abcam KLRC4-KLRK1 antibody (Abcam, ab35033) was used in flow cytometry on human samples . Cancer Lett (2015) ncbi
BD Biosciences
mouse monoclonal (1D11)
  • flow cytometry; human; loading ...; fig s2f
BD Biosciences KLRC4-KLRK1 antibody (BD Biosciences, 1D11) was used in flow cytometry on human samples (fig s2f). JCI Insight (2017) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human; loading ...; fig 3b
In order to evaluate the effectiveness of adoptive natural killer cell therapy against the pulmonary metastasis of Ewing sarcoma, BD Biosciences KLRC4-KLRK1 antibody (BD Pharmingen, 1D11) was used in flow cytometry on human samples (fig 3b). Oncoimmunology (2017) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human; loading ...; fig 5a
In order to investigate the role of natural killer cells to lymphangioleiomyomatosis pathogenesis, BD Biosciences KLRC4-KLRK1 antibody (BD Biosciences, 1D11) was used in flow cytometry on human samples (fig 5a). JCI Insight (2016) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human; fig 5
BD Biosciences KLRC4-KLRK1 antibody (BD Biosciences, 1D11) was used in flow cytometry on human samples (fig 5). PLoS Pathog (2016) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human; loading ...; fig 1e
BD Biosciences KLRC4-KLRK1 antibody (BD Biosciences, 1D11) was used in flow cytometry on human samples (fig 1e). J Immunol (2016) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human; 1:100; fig 1
In order to elucidate the marked reduction of Nkp44/Nkp46-double positive natural killer cells by celiac disease-related inflammation, BD Biosciences KLRC4-KLRK1 antibody (Becton Dickinson, 1D11) was used in flow cytometry on human samples at 1:100 (fig 1). PLoS ONE (2016) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human; tbl s2
In order to examine the early impact of viral replicative capacity on HIV-1 immunopathogenesis, BD Biosciences KLRC4-KLRK1 antibody (BD Biosciences, 1D11) was used in flow cytometry on human samples (tbl s2). Proc Natl Acad Sci U S A (2015) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human; fig s1
BD Biosciences KLRC4-KLRK1 antibody (BD Biosciences, 1D11) was used in flow cytometry on human samples (fig s1). J Immunol (2015) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human; tbl s5
In order to investigate when Vgamma9Vdelta2 T cells develop, BD Biosciences KLRC4-KLRK1 antibody (BD Bioscience, 1D11) was used in flow cytometry on human samples (tbl s5). Proc Natl Acad Sci U S A (2015) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human; fig s1
In order to analyze cancer cell plasticity autonomous stimulation by human NKG2D lymphocyte receptor coexpressed with its ligands on cancer cells, BD Biosciences KLRC4-KLRK1 antibody (BD Pharmingen, 1D11) was used in flow cytometry on human samples (fig s1). PLoS ONE (2014) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human
BD Biosciences KLRC4-KLRK1 antibody (BD, 1D11) was used in flow cytometry on human samples . Clin Cancer Res (2014) ncbi
mouse monoclonal (1D11)
  • flow cytometry; human
BD Biosciences KLRC4-KLRK1 antibody (BD/Pharmingen, 1D11) was used in flow cytometry on human samples . J Infect Dis (2014) ncbi
Articles Reviewed
  1. Choi J, Lee E, Kim S, Park S, Oh S, Kang J, et al. Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer. BMC Cancer. 2019;19:817 pubmed publisher
  2. Meckiff B, Ladell K, McLaren J, Ryan G, Leese A, James E, et al. Primary EBV Infection Induces an Acute Wave of Activated Antigen-Specific Cytotoxic CD4+ T Cells. J Immunol. 2019;203:1276-1287 pubmed publisher
  3. Ingegnere T, Mariotti F, Pelosi A, Quintarelli C, De Angelis B, Tumino N, et al. Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing. Front Immunol. 2019;10:957 pubmed publisher
  4. Dias J, Boulouis C, Gorin J, van den Biggelaar R, Lal K, Gibbs A, et al. The CD4-CD8- MAIT cell subpopulation is a functionally distinct subset developmentally related to the main CD8+ MAIT cell pool. Proc Natl Acad Sci U S A. 2018;115:E11513-E11522 pubmed publisher
  5. Dassa L, Seidel E, Oiknine Djian E, Yamin R, Wolf D, Le Trilling V, et al. The Human Cytomegalovirus Protein UL148A Downregulates the NK Cell-Activating Ligand MICA To Avoid NK Cell Attack. J Virol. 2018;92: pubmed publisher
  6. Tobin L, Mavinkurve M, Carolan E, Kinlen D, O Brien E, Little M, et al. NK cells in childhood obesity are activated, metabolically stressed, and functionally deficient. JCI Insight. 2017;2: pubmed publisher
  7. Herndler Brandstetter D, Shan L, Yao Y, Stecher C, Plajer V, Lietzenmayer M, et al. Humanized mouse model supports development, function, and tissue residency of human natural killer cells. Proc Natl Acad Sci U S A. 2017;114:E9626-E9634 pubmed publisher
  8. Salio M, Gasser O, González López C, Martens A, Veerapen N, Gileadi U, et al. Activation of Human Mucosal-Associated Invariant T Cells Induces CD40L-Dependent Maturation of Monocyte-Derived and Primary Dendritic Cells. J Immunol. 2017;199:2631-2638 pubmed publisher
  9. Delso Vallejo M, Kollet J, Koehl U, Huppert V. Influence of Irradiated Peripheral Blood Mononuclear Cells on Both Ex Vivo Proliferation of Human Natural Killer Cells and Change in Cellular Property. Front Immunol. 2017;8:854 pubmed publisher
  10. Jensen H, Potempa M, Gotthardt D, Lanier L. Cutting Edge: IL-2-Induced Expression of the Amino Acid Transporters SLC1A5 and CD98 Is a Prerequisite for NKG2D-Mediated Activation of Human NK Cells. J Immunol. 2017;199:1967-1972 pubmed publisher
  11. Domae E, Hirai Y, Ikeo T, Goda S, Shimizu Y. Cytokine-mediated activation of human ex vivo-expanded V?9V?2 T cells. Oncotarget. 2017;8:45928-45942 pubmed publisher
  12. Tong A, Hashem H, Eid S, Allen F, Kingsley D, Huang A. Adoptive natural killer cell therapy is effective in reducing pulmonary metastasis of Ewing sarcoma. Oncoimmunology. 2017;6:e1303586 pubmed publisher
  13. Djaoud Z, Guethlein L, Horowitz A, Azzi T, Nemat Gorgani N, Olive D, et al. Two alternate strategies for innate immunity to Epstein-Barr virus: One using NK cells and the other NK cells and ?? T cells. J Exp Med. 2017;214:1827-1841 pubmed publisher
  14. Tripathi D, Venkatasubramanian S, Cheekatla S, Paidipally P, Welch E, Tvinnereim A, et al. A TLR9 agonist promotes IL-22-dependent pancreatic islet allograft survival in type 1 diabetic mice. Nat Commun. 2016;7:13896 pubmed publisher
  15. Tomic A, Varanasi P, Golemac M, Malic S, Riese P, Borst E, et al. Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D Ligand. PLoS Pathog. 2016;12:e1006015 pubmed publisher
  16. Osterburg A, Nelson R, Yaniv B, Foot R, Donica W, Nashu M, et al. NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function decline. JCI Insight. 2016;1:e87270 pubmed publisher
  17. Pachnio A, Ciáurriz M, Begum J, Lal N, Zuo J, Beggs A, et al. Cytomegalovirus Infection Leads to Development of High Frequencies of Cytotoxic Virus-Specific CD4+ T Cells Targeted to Vascular Endothelium. PLoS Pathog. 2016;12:e1005832 pubmed publisher
  18. Sadallah S, Schmied L, Eken C, Charoudeh H, Amicarella F, Schifferli J. Platelet-Derived Ectosomes Reduce NK Cell Function. J Immunol. 2016;197:1663-71 pubmed publisher
  19. Zanetti S, Ziblat A, Torres N, Zwirner N, Bouzat C. Expression and Functional Role of ?7 Nicotinic Receptor in Human Cytokine-stimulated Natural Killer (NK) Cells. J Biol Chem. 2016;291:16541-52 pubmed publisher
  20. Loyon R, Picard E, Mauvais O, Queiroz L, Mougey V, Pallandre J, et al. IL-21-Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor-Dependent Manner. J Immunol. 2016;197:85-96 pubmed publisher
  21. Kwon H, Choi G, Ryu S, Kwon S, Kim S, Booth C, et al. Stepwise phosphorylation of p65 promotes NF-?B activation and NK cell responses during target cell recognition. Nat Commun. 2016;7:11686 pubmed publisher
  22. Yin W, Tong S, Zhang Q, Shao J, Liu Q, Peng H, et al. Functional dichotomy of Vδ2 γδ T cells in chronic hepatitis C virus infections: role in cytotoxicity but not for IFN-γ production. Sci Rep. 2016;6:26296 pubmed publisher
  23. Marafini I, Monteleone I, Di Fusco D, Sedda S, Cupi M, Fina D, et al. Celiac Disease-Related Inflammation Is Marked by Reduction of Nkp44/Nkp46-Double Positive Natural Killer Cells. PLoS ONE. 2016;11:e0155103 pubmed publisher
  24. Acebes Huerta A, Lorenzo Herrero S, Folgueras A, Huergo Zapico L, Lopez Larrea C, Lopez Soto A, et al. Drug-induced hyperploidy stimulates an antitumor NK cell response mediated by NKG2D and DNAM-1 receptors. Oncoimmunology. 2016;5:e1074378 pubmed
  25. Kanderová V, Kuzilkova D, Stuchly J, Vaskova M, Brdicka T, Fiser K, et al. High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells. Mol Cell Proteomics. 2016;15:1246-61 pubmed publisher
  26. Fernandez L, Valentin J, Zalacain M, Leung W, Patino Garcia A, Perez Martinez A. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner. Cancer Lett. 2015;368:54-63 pubmed publisher
  27. Rancan C, Schirrmann L, Hüls C, Zeidler R, Moosmann A. Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells. PLoS Pathog. 2015;11:e1004906 pubmed publisher
  28. Dyring Andersen B, Bonefeld C, Bzorek M, Løvendorf M, Lauritsen J, Skov L, et al. The Vitamin D Analogue Calcipotriol Reduces the Frequency of CD8+ IL-17+ T Cells in Psoriasis Lesions. Scand J Immunol. 2015;82:84-91 pubmed publisher
  29. Zhou J, Amran F, Kramski M, Angelovich T, Elliott J, Hearps A, et al. An NK Cell Population Lacking FcRγ Is Expanded in Chronically Infected HIV Patients. J Immunol. 2015;194:4688-97 pubmed publisher
  30. Claiborne D, Prince J, Scully E, Macharia G, Micci L, Lawson B, et al. Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression. Proc Natl Acad Sci U S A. 2015;112:E1480-9 pubmed publisher
  31. Marquardt N, Béziat V, Nyström S, Hengst J, Ivarsson M, Kekäläinen E, et al. Cutting edge: identification and characterization of human intrahepatic CD49a+ NK cells. J Immunol. 2015;194:2467-71 pubmed publisher
  32. Dimova T, Brouwer M, Gosselin F, Tassignon J, Leo O, Donner C, et al. Effector Vγ9Vδ2 T cells dominate the human fetal γδ T-cell repertoire. Proc Natl Acad Sci U S A. 2015;112:E556-65 pubmed publisher
  33. Liu H, Yang B, Sun T, Lin L, Hu Y, Deng M, et al. Specific growth inhibition of ErbB2‑expressing human breast cancer cells by genetically modified NK‑92 cells. Oncol Rep. 2015;33:95-102 pubmed publisher
  34. Ziblat A, Domaica C, Spallanzani R, Iraolagoitia X, Rossi L, Avila D, et al. IL-27 stimulates human NK-cell effector functions and primes NK cells for IL-18 responsiveness. Eur J Immunol. 2015;45:192-202 pubmed publisher
  35. Cai X, Dai Z, Reeves R, Caballero Benítez A, Duran K, Delrow J, et al. Autonomous stimulation of cancer cell plasticity by the human NKG2D lymphocyte receptor coexpressed with its ligands on cancer cells. PLoS ONE. 2014;9:e108942 pubmed publisher
  36. Sullivan E, Jeha S, Kang G, Cheng C, Rooney B, Holladay M, et al. NK cell genotype and phenotype at diagnosis of acute lymphoblastic leukemia correlate with postinduction residual disease. Clin Cancer Res. 2014;20:5986-94 pubmed publisher
  37. Watanabe M, Kudo Y, Kawano M, Nakayama M, Nakamura K, Kameda M, et al. NKG2D functions as an activating receptor on natural killer cells in the common marmoset (Callithrix jacchus). Int Immunol. 2014;26:597-606 pubmed publisher
  38. Rossi G, Pengo G, Caldin M, Palumbo Piccionello A, Steiner J, Cohen N, et al. Comparison of microbiological, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel disease. PLoS ONE. 2014;9:e94699 pubmed publisher
  39. Cairo C, Longinaker N, Cappelli G, Leke R, Ondo M, Djokam R, et al. Cord blood V?2V?2 T cells provide a molecular marker for the influence of pregnancy-associated malaria on neonatal immunity. J Infect Dis. 2014;209:1653-62 pubmed publisher
  40. Volonté A, Di Tomaso T, Spinelli M, Todaro M, Sanvito F, Albarello L, et al. Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. J Immunol. 2014;192:523-32 pubmed publisher